Ricardo Dolmetsch Ph.D.
Net Worth
Last updated:
What is Ricardo Dolmetsch Ph.D. net worth?
The estimated net worth of Dr. Ricardo Dolmetsch Ph.D. is at least $5,591,969 as of 18 Sep 2023. He owns shares worth $2,496,813 as insider, has earned $590,556 from insider trading and has received compensation worth at least $2,504,600 in uniQure N.V..
What is the salary of Ricardo Dolmetsch Ph.D.?
Dr. Ricardo Dolmetsch Ph.D. salary is $626,150 per year as Pres of R&D in uniQure N.V..
How old is Ricardo Dolmetsch Ph.D.?
Dr. Ricardo Dolmetsch Ph.D. is 56 years old, born in 1969.
What stocks does Ricardo Dolmetsch Ph.D. currently own?
As insider, Dr. Ricardo Dolmetsch Ph.D. owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| uniQure N.V. (QURE) | Pres of R&D | 163,404 | $15.28 | $2,496,813 |
What does uniQure N.V. do?
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Ricardo Dolmetsch Ph.D. insider trading
uniQure N.V.
Dr. Ricardo Dolmetsch Ph.D. has made 6 insider trades between 2021-2023, according to the Form 4 filled with the SEC. Most recently he sold 5,841 units of QURE stock worth $43,574 on 18 Sep 2023.
The largest trade he's ever made was exercising 8,603 units of QURE stock on 16 Sep 2021. As of 18 Sep 2023 he still owns at least 163,404 units of QURE stock.
uniQure N.V. key executives
uniQure N.V. executives and other stock owners filed with the SEC:
- Dr. Alexander E. Kuta Ph.D. (65) Executive Vice President of Quality & Regulatory
- Dr. Ricardo Dolmetsch Ph.D. (56) Pres of R&D
- Mr. Christian Klemt (52) Chief Financial Officer, Principal Financial Officer & GM of Amsterdam Site
- Mr. Matthew Craig Kapusta (53) Chief Executive Officer & Executive Director